Clinical Study to Analyze the Safety and Efficacy of Molixan® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19)
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Glutathione/inosine (Primary) ; Glutathione/inosine (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Sponsors BAM
Most Recent Events
- 08 Oct 2021 Planned End Date changed from 19 Oct 2021 to 30 Sep 2022.
- 08 Oct 2021 Planned primary completion date changed from 19 Aug 2021 to 31 May 2022.
- 12 Mar 2021 Status changed from not yet recruiting to recruiting.